IL-6, LIF, and TNF-α regulation of GM-CSF inhibition of osteoclastogenesis in vitro

被引:34
作者
Gorny, G
Shaw, A
Oursler, MJ
机构
[1] Mayo Clin & Mayo Fdn, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA
[2] Univ Minnesota, Dept Biol, Duluth, MN 55812 USA
关键词
osteoclastogenesis; GM-CSF; IGF-I; IGF-II; IL-6; LIF; TNF-alpha;
D O I
10.1016/j.yexcr.2003.11.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
During pathological bone loss, factors that are both stimulatory and inhibitory for osteoclast differentiation are over-expressed. Despite the presence of inhibitory factors, osteoclast differentiation is significantly enhanced to bring about bone loss. To examine the hypothesis that stimulatory growth factors overcome the effects of inhibitory factors, we have examined the ability of IGF-I, IGF-II, IL-6, LIF, and TNF-alpha to overcome osteoclast differentiation inhibition by GM-CSF in vitro. Osteoclast numbers were significantly elevated by treatment with IGF-I, IGF-II, IL-6, LIE, or TNF-alpha alone whereas GM-CSF treatment of stromal cell and osteoclast co-cultures inhibited osteoclast formation. IL-6, LIF, or TNF-alpha, individually overcame GM-CSF inhibition whereas neither IGF-I nor IGF-II treatment overcame GM-CSF inhibition. Interestingly, GM-CSF addition with either IL-6 or TNF-alpha increased osteoclast numbers beyond that seen with either IL-6 or TNF-a alone. Combined treatment with TNF-a and IL-6 showed a significant increase in osteoclast numbers with GM-CSF addition. Examination of the impacts of these growth factors individually or in combinations on stromal cell M-CSF, RANKL, and OPG expression revealed a complex pattern involving alterations in the ratio of RANKL to OPG and/or M-CSF expression as candidate mechanisms of action. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 48 条
[1]
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors [J].
Atkins, GJ ;
Haynes, DR ;
Graves, SE ;
Evdokiou, A ;
Hay, S ;
Bouralexis, S ;
Findlay, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) :640-649
[2]
Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation [J].
Atkins, GJ ;
Haynes, DR ;
Geary, SM ;
Loric, M ;
Crotti, TN ;
Findlay, DM .
BONE, 2000, 26 (06) :653-661
[3]
BASYLINK DJ, 1992, ENDOCRINOLOGY, V131, P1075
[4]
CAMPBELL IK, 1991, J IMMUNOL, V147, P1238
[5]
The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts [J].
Chihara, K ;
Sugimoto, T .
HORMONE RESEARCH, 1997, 48 :45-49
[6]
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[7]
Clohisy DR, 1996, J ORTHOPAED RES, V14, P396
[8]
Characterization and function of the receptor for IGF-I in human preosteoclastic cells [J].
Fiorelli, G ;
Formigli, L ;
Orlandini, SZ ;
Gori, F ;
Falchetti, A ;
Morelli, A ;
Tanini, A ;
Benvenuti, S ;
Brandi, ML .
BONE, 1996, 18 (03) :269-276
[9]
The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1,-3,-6, and-11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells [J].
Fujikawa, Y ;
Sabokbar, A ;
Neale, SD ;
Itonaga, I ;
Torisu, T ;
Athanasou, NA .
BONE, 2001, 28 (03) :261-267
[10]
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival [J].
Gingery, A ;
Bradley, E ;
Shaw, A ;
Oursler, MJ .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (01) :165-179